Trade BioMarin Pharmaceutical Inc - BMRN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.32 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 58.57 |
| Open | 57.97 |
| 1-Year Change | -36.16% |
| Day's Range | 57.97 - 59.44 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 59.10 | 1.13 | 1.95% | 57.97 | 59.51 | 57.60 |
| Apr 16, 2025 | 58.57 | -0.79 | -1.33% | 59.36 | 59.82 | 58.07 |
| Apr 15, 2025 | 59.69 | 0.14 | 0.24% | 59.55 | 60.82 | 59.44 |
| Apr 14, 2025 | 59.36 | 2.01 | 3.50% | 57.35 | 59.90 | 56.93 |
| Apr 11, 2025 | 56.73 | 0.69 | 1.23% | 56.04 | 56.83 | 55.02 |
| Apr 10, 2025 | 56.28 | -1.05 | -1.83% | 57.33 | 57.95 | 54.55 |
| Apr 9, 2025 | 59.01 | 4.86 | 8.98% | 54.15 | 59.77 | 52.83 |
| Apr 8, 2025 | 55.77 | -4.44 | -7.37% | 60.21 | 60.88 | 55.40 |
| Apr 7, 2025 | 59.09 | 0.24 | 0.41% | 58.85 | 60.21 | 56.38 |
| Apr 4, 2025 | 60.16 | -5.84 | -8.85% | 66.00 | 66.20 | 59.81 |
| Apr 3, 2025 | 67.39 | 0.47 | 0.70% | 66.92 | 68.26 | 66.55 |
| Apr 2, 2025 | 68.05 | 0.17 | 0.25% | 67.88 | 68.34 | 67.33 |
| Apr 1, 2025 | 67.85 | -2.00 | -2.86% | 69.85 | 70.05 | 67.77 |
| Mar 31, 2025 | 70.36 | -0.04 | -0.06% | 70.40 | 70.95 | 69.02 |
| Mar 28, 2025 | 71.35 | -0.20 | -0.28% | 71.55 | 72.33 | 70.63 |
| Mar 27, 2025 | 72.48 | 1.06 | 1.48% | 71.42 | 73.10 | 71.42 |
| Mar 26, 2025 | 71.13 | 0.50 | 0.71% | 70.63 | 71.75 | 69.46 |
| Mar 25, 2025 | 71.50 | 0.02 | 0.03% | 71.48 | 72.17 | 70.82 |
| Mar 24, 2025 | 71.67 | 0.49 | 0.69% | 71.18 | 72.31 | 70.40 |
| Mar 21, 2025 | 70.86 | -0.09 | -0.13% | 70.95 | 71.97 | 70.32 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.
Equity composition
Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.
| Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com